logo-loader
RNS
viewTissue Regenix Group PLC

Additional manufacturing capacity secured

/**/ sup{font-size:80%} .l{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.l{}p.y{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; text-align: center}p.z{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: 115%}p.aa{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm}table.ab{border-collapse:collapse}td.t{width:253.15pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.s{width:171.15pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.r{width:253.15pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.q{width:171.15pt;border:none;padding:0cm 5.4pt 0cm 5.4pt} td.p{width:253.15pt;border:none;border-bottom: solid #D7D7D7 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.o{width:171.15pt;border:none;border-bottom: solid #D7D7D7 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.ac{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: 115%; margin-bottom: 0cm} /**/
RNS Number : 1542J
Tissue Regenix Group PLC
15 August 2019
 

Tissue Regenix Group plc

 

Additional manufacturing capacity secured as part of expansion strategy

 

Leeds, 15 August 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group"), the regenerative medical devices company, announces that it has signed a 10-year lease agreement on a 21,000 sq. ft. facility to expand processing capacity at its manufacturing base in San Antonio, Texas. The agreement also includes the option to purchase the facility at a later date. 

 

The new facility, situated on adjacent land to the Group's current 13,700 sq. ft. facility, will be brought on stream in a phased plan to meet the growing commercial demand for the Company's novel product portfolio. Phase one will commence immediately with part of the new building being converted into office, distribution and warehouse space, allowing for additional clean rooms to be built in the original facility, which are expected to be operational by the end of H1 2020.

 

Over time, it is planned for further processing and packaging clean rooms to be built in the new facility therefore, increasing the Company's ability to process more tissue and produce products. The new facility underpins the Company's strategy of building strategic partnerships, accelerating US market penetration and pursuing geographic expansion opportunities.

 

Gareth Jones, Interim CEO of Tissue Regenix Group, commented:

"I am delighted that we have secured this additional facility to support our ambitious growth plans. The Group has undertaken a number of operational initiatives in order to increase production capabilities and meet the growing market demand for our products. Having commenced a second shift at the beginning of the year in our current facility in San Antonio, the phased build out of this new facility will allow us to meet the growing requirements of our customers well into the future."

 

 

For more Information:

 

Tissue Regenix Group plc

Caitlin Pearson, Head of Communications  

Tel: 0330 430 3073 / 07920272441

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Jonathan Senior / Alex Price / Ben Maddison

Tel:  0207 710 7600

 

 

 

FTI Consulting 

Brett Pollard / Victoria Foster Mitchell / Mary Whittow

Tel: 0203 727 1000

 

 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

 

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCCKPDBPBKKAFD

Quick facts: Tissue Regenix Group PLC

Price: 0.65

Market: AIM
Market Cap: £7.85 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

RNS

Second Price Monitoring Extn

19 hours, 48 minutes ago

Price Monitoring Extension

19 hours, 53 minutes ago

Holding(s) in Company

3 weeks, 5 days ago

Trading Update

3 weeks, 5 days ago

Holding(s) in Company

4 weeks ago